137 related articles for article (PubMed ID: 35166870)
1. [Radiotherapy dose escalation does not improve local control in patients with esophageal cancer after definitive radiochemotherapy: the ARTDECO randomized phase III trial].
Fokas E; Martin D; Rödel C
Strahlenther Onkol; 2022 Apr; 198(4):397-399. PubMed ID: 35166870
[No Abstract] [Full Text] [Related]
2. [Dose-escalated radiotherapy in esophageal cancer: A review of the literature].
Boustani J; Créhange G
Cancer Radiother; 2022 Oct; 26(6-7):884-889. PubMed ID: 36008261
[TBL] [Abstract][Full Text] [Related]
3. SCOPE 2 - Still Answering the Unanswered Questions in Oesophageal Radiotherapy? SCOPE 2: a Randomised Phase II/III Trial to Study Radiotherapy Dose Escalation in Patients with Oesophageal Cancer Treated with Definitive Chemoradiation with an Embedded Phase II Trial for Patients with a Poor Early Response using Positron Emission Tomography/Computed Tomography.
Bridges S; Thomas B; Radhakrishna G; Hawkins M; Holborow A; Hurt C; Mukherjee S; Nixon L; Crosby T; Gwynne S
Clin Oncol (R Coll Radiol); 2022 Jul; 34(7):e269-e280. PubMed ID: 35466013
[TBL] [Abstract][Full Text] [Related]
4. Prospective, open, multicentre Phase I/II trial to assess safety and efficacy of neoadjuvant radiochemotherapy with docetaxel and cisplatin for esophageal carcinoma.
Ma HB; Di ZL; Wen J; Ke Y; Sun X; Ren J
Jpn J Clin Oncol; 2015 Feb; 45(2):169-75. PubMed ID: 25416813
[TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant concurrent chemoradiotherapy followed by definitive high-dose radiotherapy or surgery for operable thoracic esophageal carcinoma.
Murakami M; Kuroda Y; Okamoto Y; Kono K; Yoden E; Kusumi F; Hajiro K; Matsusue S; Takeda H
Int J Radiat Oncol Biol Phys; 1998 Mar; 40(5):1049-59. PubMed ID: 9539559
[TBL] [Abstract][Full Text] [Related]
6. [Prognostic analysis of definitive radiotherapy for early esophageal carcinoma(T1-2N0M0): a multi-center retrospective study of Jing-Jin-ji Esophageal and Esophagogastric Cancer Radiotherapy Oncology Group].
Lu N; Wang X; Li C; Wang L; Chen JQ; Zhang WC; Wang XM; Ge XL; Shen WB; Hu MM; Yuan QQ; Xu YG; Hao CL; Zhou ZG; Qie S; Xiao ZF; Zhu SC; Han C; Qiao XY; Pang QS; Wang P; Zhao YD; Sun XC; Zhang KX; Li L; Li GF; Liu ML; Wang YD
Zhonghua Zhong Liu Za Zhi; 2020 Feb; 42(2):139-144. PubMed ID: 32135649
[No Abstract] [Full Text] [Related]
7. Radiation Dose Escalation in Esophageal Cancer Revisited: A Contemporary Analysis of the National Cancer Data Base, 2004 to 2012.
Brower JV; Chen S; Bassetti MF; Yu M; Harari PM; Ritter MA; Baschnagel AM
Int J Radiat Oncol Biol Phys; 2016 Dec; 96(5):985-993. PubMed ID: 27869098
[TBL] [Abstract][Full Text] [Related]
8. Definitive radiochemotherapy in esophageal cancer - a single institution experience.
Anderluh F; Toplak M; Velenik V; Oblak I; Ermenc AS; Peressutti AJ; But-Hadzic J; Vidmar MS
Radiol Oncol; 2019 Nov; 53(4):480-487. PubMed ID: 31747382
[TBL] [Abstract][Full Text] [Related]
9. Comparison of salvage chemoradiation versus salvage surgery for recurrent esophageal squamous cell carcinoma after definitive radiochemotherapy or radiotherapy alone.
Chen Y; Lu Y; Wang Y; Yang H; Xia Y; Chen M; Song H; Li T; Li D; Wang J; Li S; Wang J
Dis Esophagus; 2014; 27(2):134-40. PubMed ID: 23088212
[TBL] [Abstract][Full Text] [Related]
10. Chemoradiotherapy and radiotherapy alone in patients with esophageal cancer aged 80 years or older based on the Comprehensive Registry of Esophageal Cancer in Japan.
Jingu K; Numasaki H; Toh Y; Nemoto K; Uno T; Doki Y; Matsubara H
Esophagus; 2020 Jul; 17(3):223-229. PubMed ID: 32088786
[TBL] [Abstract][Full Text] [Related]
11. A phase-II/III randomized controlled trial of adjuvant radiotherapy or concurrent chemoradiotherapy after surgery versus surgery alone in patients with stage-IIB/III esophageal squamous cell carcinoma.
Ni W; Yu S; Zhang W; Xiao Z; Zhou Z; Chen D; Feng Q; Liang J; Lv J; Gao S; Mao Y; Xue Q; Sun K; Liu X; Fang D; Li J; Wang D
BMC Cancer; 2020 Feb; 20(1):130. PubMed ID: 32070309
[TBL] [Abstract][Full Text] [Related]
12. Local Control and Toxicity of a Simultaneous Integrated Boost for Dose Escalation in Locally Advanced Esophageal Cancer: Interim Results from a Prospective Phase I/II Trial.
Welsh JW; Seyedin SN; Allen PK; Hofstetter WL; Ajani JA; Chang JY; Gomez DR; Amini A; Swisher SG; Blum MA; Younes AI; Nguyen QN; Minsky BD; Erasmus JJ; Lee JH; Bhutani M; Komaki RU
J Thorac Oncol; 2017 Feb; 12(2):375-382. PubMed ID: 27794500
[TBL] [Abstract][Full Text] [Related]
13. Radiation dose escalation by simultaneous modulated accelerated radiotherapy combined with chemotherapy for esophageal cancer: a phase II study.
Chen J; Guo H; Zhai T; Chang D; Chen Z; Huang R; Zhang W; Lin K; Guo L; Zhou M; Li D; Li D; Chen C
Oncotarget; 2016 Apr; 7(16):22711-9. PubMed ID: 26992206
[TBL] [Abstract][Full Text] [Related]
14. Feasibility of endoscopic mucosal resection as salvage treatment for patients with local failure after definitive chemoradiotherapy for stage IB, II, and III esophageal squamous cell cancer.
Makazu M; Kato K; Takisawa H; Yoshinaga S; Oda I; Saito Y; Mayahara H; Ito Y; Itami J; Hamaguchi T; Yamada Y; Shimada Y
Dis Esophagus; 2014 Jan; 27(1):42-9. PubMed ID: 23442160
[TBL] [Abstract][Full Text] [Related]
15. Salvage radiotherapy in patients with local recurrent esophageal cancer after radical radiochemotherapy.
Zhou ZG; Zhen CJ; Bai WW; Zhang P; Qiao XY; Liang JL; Gao XS; Wang SS
Radiat Oncol; 2015 Feb; 10():54. PubMed ID: 25888966
[TBL] [Abstract][Full Text] [Related]
16. Current status of radiotherapy for patients with thoracic esophageal cancer in Japan, based on the Comprehensive Registry of Esophageal Cancer in Japan from 2009 to 2011 by the Japan Esophageal Society.
Toh Y; Numasaki H; Tachimori Y; Uno T; Jingu K; Nemoto K; Matsubara H
Esophagus; 2020 Jan; 17(1):25-32. PubMed ID: 31473871
[TBL] [Abstract][Full Text] [Related]
17. Dose escalation intensity-modulated radiotherapy-based concurrent chemoradiotherapy is effective for advanced-stage thoracic esophageal squamous cell carcinoma.
Chang CL; Tsai HC; Lin WC; Chang JH; Hsu HL; Chow JM; Yuan KS; Wu ATH; Wu SY
Radiother Oncol; 2017 Oct; 125(1):73-79. PubMed ID: 28923576
[TBL] [Abstract][Full Text] [Related]
18. Esophagectomy after concurrent chemoradiotherapy improves locoregional control in clinical stage II or III esophageal cancer patients.
Liao Z; Zhang Z; Jin J; Ajani JA; Swisher SG; Stevens CW; Ho L; Smythe R; Vaporciyan AA; Putnam JB; Walsh GL; Roth JA; Yao JC; Allen PK; Cox JD; Komaki R
Int J Radiat Oncol Biol Phys; 2004 Dec; 60(5):1484-93. PubMed ID: 15590179
[TBL] [Abstract][Full Text] [Related]
19. Results of a Phase 1/2 Trial of Chemoradiotherapy With Simultaneous Integrated Boost of Radiotherapy Dose in Unresectable Locally Advanced Esophageal Cancer.
Chen D; Menon H; Verma V; Seyedin SN; Ajani JA; Hofstetter WL; Nguyen QN; Chang JY; Gomez DR; Amini A; Swisher SG; Blum MA; Younes AI; Barsoumian HB; Erasmus JJ; Lee JH; Bhutani MS; Hess KR; Minsky BD; Welsh JW
JAMA Oncol; 2019 Nov; 5(11):1597-1604. PubMed ID: 31529018
[TBL] [Abstract][Full Text] [Related]
20. KEYNOTE-975 study design: a Phase III study of definitive chemoradiotherapy plus pembrolizumab in patients with esophageal carcinoma.
Shah MA; Bennouna J; Doi T; Shen L; Kato K; Adenis A; Mamon HJ; Moehler M; Fu X; Cho BC; Bordia S; Bhagia P; Shih CS; Desai A; Enzinger P
Future Oncol; 2021 Apr; 17(10):1143-1153. PubMed ID: 33533655
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
